Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study-Reference-Cited by-同舟云学术

Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study

Published:2022-10 Issue:4 Volume:85 Page:e109-e111
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Yan Yan^ORCID,Davgadorj Chantsalmaa,Lyu Chunyan,Zhang Shiliang,Qiu Yuanwang

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference10 articles.

1. Effectiveness of COVID-19 vaccines;Syed;J Infect,2022

2. COVID-19 vaccine development: milestones, lessons and prospects;Li;Signal Transduct Target Ther,2022

3. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine;Liu;Cell Discov,2022

4. Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary;Tre-Hardy;J Infect,2021

5. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis;Marra;J Infect,2022

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of tuberculosis patients and the role of forensic medicine in COVID-19 pandemic;Indian Journal of Tuberculosis;2024-10

2. People living with HIV with the Omicron variant infection have milder COVID-19 symptoms: results from a cross-sectional study;AIDS Research and Therapy;2024-08-10

3. SARS-CoV-2 Vaccine-Related Liver Failure: Active Hepatitis B and Comprehensive Literature Analysis;New Topics in Vaccine Development [Working Title];2023-11-06

4. SARS-CoV-2 and chronic hepatitis B: Focusing on the possible consequences of co-infection;Journal of Clinical Virology Plus;2023-11

5. Willingness of people living with HIV to receive a second COVID-19 booster dose: a multicenter cross-sectional study in China;Frontiers in Public Health;2023-08-23